Special Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Ovarian Cancer Issue

1

Introduction

00:00 • 2min

2

DuoO's HRD Test Negative Trial

01:31 • 4min

3

The Role of Checkpoint Inhibitors in Ovarian Cancer

05:26 • 3min

4

The Role of I.O. In Ovarian Cancer

08:13 • 3min

5

The Primary Maintenance Issue in Ovarian Cancer

11:09 • 2min

6

How to Choose the Right Treatment for Your Patient

13:14 • 3min

7

Niraprib and the Knee-Allegent

16:12 • 2min

8

The Role of PARP in Ovarian Cancer

17:44 • 2min

9

The Role of PARP in Primary Maintenance of Ovarian Cancer

19:30 • 5min

10

The Relationship Between BRACCA and MDS on PARP Inhibitors

24:35 • 4min

11

The Importance of Risk Reduction in Breast Cancer

28:08 • 3min

12

The Role of PARP Inhibitors in Later Line Situations

31:07 • 3min

13

The FDA's Decision to Remove Later Line Opportunities for PARP Patients

34:05 • 2min

14

Mervituximab Antibody Drug Conjugate in Ovarian Cancer

36:03 • 2min

15

The Role of Eye Toxicity in CNS Treatments

38:22 • 3min

16

Upri: A First Line Antibody Drug Conjugate

41:16 • 3min

17

NAPI2B Low Patients Benefit From Targeted Therapy

44:13 • 2min

18

The Tolerance of UPRI in Patients With Platinum Resistance

45:49 • 2min

19

The Future of Tumor Treating Fields

47:45 • 3min

20

The Effects of Pacletaxel on Ovarian Cancer

50:24 • 2min

21

The Different Types of Dermatologic Toxicities With ADCs

52:00 • 2min

22

The Future of Antibody Drugs

54:09 • 3min